000999

600535

<p>CR Sanjiu faces more concerns after acquiring TASLY. Recently, due to the impact of the Anhui centralized procurement policy, the stock price has plummeted, with a market value evaporating by over 10 billion. As a core product, if 999 Cold Medicine is included in the centralized procurement, it will severely affect performance. The market holds a pessimistic view on the future performance of pharmaceutical companies, leading investors to sell off their shares</p>

- The article discusses the challenges faced by pharmaceutical company China Resources Sanjiu amid new procurement policies in Anhui, which have led to significant stock price declines.  
- The introduction of centralized procurement for popular OTC products, including its flagship 999 cold medicine, raises concerns about profit margins and market share, as companies may need to cut prices by at least 50%.  
- Despite a slight revenue increase, the company's future growth prospects are uncertain due to regulatory pressures and increased competition, leading to a cautious outlook for investors.

Why is CR Sanjiu being shorted?